Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

SUPN Relative to the S&P 500

SUPN Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Supernus Pharmaceuticals, Inc. (NASD:SUPN) seasonal charts above shows that a Buy Date of December 13 and a Sell Date of March 7 has resulted in a geometric average return of 6.8% above the benchmark rate of the S&P 500 Total Return Index over the past 12 years. This seasonal timeframe has shown positive results compared to the benchmark in 11 of those periods. This is an excellent rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 12 years by an average of 6.71% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company’s diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

To download SUPN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: SUPN